Evommune (EVMN) Capital Expenditures (2025 - 2026)
Evommune (EVMN) posted quarterly Capital Expenditures of $38000.0 for Q1 2026, up 139.58% quarter-over-quarter from -$96000.0 in Q4 2025.
Powered by 
Analysis
Evommune (EVMN) Capital Expenditures (2025 - 2026) Analysis & Trends
Evommune (EVMN) has reported Capital Expenditures for 2 consecutive years, with $38000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures changed N/A year-over-year to $38000.0; the TTM figure through Mar 2026 stood at -$58000.0 (changed N/A YoY), while the FY2025 annual figure was $35000.0, down 60.23% from the prior year.
- Capital Expenditures climbed to $38000.0 in Q1 2026 per EVMN's latest filing, from -$96000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $38000.0 in Q1 2026 and bottomed at -$96000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Evommune | 445.19 Mn | 244.40 Mn | - | 183,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 183,000.00 |
| Mar 31, 2026 | 83,000.00 |
| Dec 31, 2025 | 104,000.00 |
| Sep 30, 2025 | 131,000.00 |